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1. INTRODUCTION 
BACKGROUND 
Tuberculosis is a major disease causing death every year 1.8 million 
worldwide and represents the leading cause of mortality resulting from a bacterial 
infection. Introduction in the 60’s of first-line drug regimen resulted in the control of 
the disease and TB was perceived as defeated.  
             In 2011, tuberculosis (TB) remained the second cause of death from 
infectious disease worldwide. It mainly affects the poorest countries of Africa and 
Southeast Asia. In 2010, according to the world health organization (WHO), TB 
incidence and prevalence were estimated at 8.8 and 12 million cases respectively 
about 1.1 million among HIV-negative people and 0.35 million among HIV-positive 
people died from TB. Most importantly, one third of the world population is infected 
with latent infection and 10% of those infected people will develop active TB in their 
life. 
              The directly observed treatment short- course (DOTS), a multiple therapy 
program developed by WHO is one of the most efficient weapons against the global 
TB epidemic. Nevertheless, the treatment success rate struggles to reach the target of 
85% .Unfortunately; first-line treatment can fail due to poor compliance which leads 
to the emergence of multidrug resistance (MDR) strains of  M.Tuberculosis. The 
number of TB drugs in preclinical and clinical development is today higher than that 
during the past 40 years.1 
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TB IN INDIA 
              India is the country with the highest burden of TB, with World Health 
Organization (WHO) statistics for 2014 giving an estimated incidence 2.2 million 
cases of TB for India out of a global incidence of 9 million. The estimated TB 
prevalence figure for 2014 is given as 2.5 million. It is estimated that about 40% of 
the Indian population is infected with TB bacteria, the vast majority of whom have 
latent rather than active TB.2 
CURRENT THERAPIES 
              Tuberculosis (TB) is caused by bacteria mycobacterium tuberculosis that 
most often affect the lungs. Tuberculosis is curable and preventable. In 1882, The 
German physician Robert Koch isolated the bacterium. Tuberculosis is contagious 
and airborne disease. 
 In 1944, streptomycin was to treat tuberculosis (TB).This amino glycoside 
interferes with protein biosynthesis through an interaction with the small 30S subunit 
of the ribosome. The discovery of Para amino salicylic acid in 1946 was quickly 
followed by the important discovery of  Isoniazide (INH), as one of the most active 
anti-TB drugs used today. Inhibition of  mycolic acids biosynthesis, one of the 
essential components of the mycobacterium cell wall was determined as the 
mechanism of action. Pyrazinamide (PZA) appeared as a potential Anti-TB drug in 
1952.    
            The TB treatment in the 1980s was a great success as it allowed to shorten the 
duration of the therapy from 9 to 6 months. Ethambutol (EMB) and Rifampin (RIF), 
the two last derivatives used in the TB first-line treatment, were discovered during the 
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60’s .Ethambutol is an ethylenediamine discovered in 1961, which affects the cell 
wall by specifically targeting the polymerization of  arabinogalactan   and 
lipoarabinomannan.  Finally, Rifampin appeared as a drug of choice for TB treatment 
around 1970, by acting on replicating and non-replicating mycobacteria.This 
derivative belongs to the rifampicin family and inhibits bacterial RNA synthesis by 
binding to the b-subunit of the DNA-dependent polymerase. 
            The current standard regimen (DOTS) for TB recommended by WHO is a 
combination of  isoniazide, rifampicin, ethambutol, and pyrazinamide for 6 months 
therapy. To treat MDR-TB, WHO recommended the use of second-line drugs which 
include amino glycosides (kanamycin, amikacin), Capreomycin, Cycloserin, Para-
aminosalicylic acid, Thionamides (Ethionamide, Proethionamide) and 
fluoroquinolones (Ciprofloxacin, Ofloxacin, Levofloxacin).1 
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 BACTERIOLOGICAL PROFILE OF MYCOBACTERIUM TUBERCULOSIS 
SPECIES 
  The mycobacterium tuberculosis complex consists of Mycobacterium bovis, 
Mycobacterium africanoum and Mycobacterium canettii, Mycobacterium capre, 
Mycobacterium microti and Mycobacterium pinnipedi.3 
 Tuberculosis (TB) is caused by the obligate human pathogen, 
Mycobacterium tuberculosis.Mycobacteria are a distinctive rod shaped, non spore 
forming aerobic bacteria that share a common property of a lipid-rich cell-wall that 
avidly retains carbol fushion dye in the presence of acidic alcohol (acid fast staining). 
Mycobacteria typically measures 0.5µm to 3µm.4 
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CELL STRUCTURE 
 Mycobacterium tuberculosis is a slow-growing aerobic rod-shaped 
bacterium. The cell wall is composed of two segments, upper and lower. Beyond the 
membrane is Peptidoglycon (PG) in covalent attachment to arabinogalactan (AG), 
which in turn is attached to mycolic acids with their long meromycolate and short α 
chain. This cell wall core complies of the mycolyl arabinogalactan-petidoglycon 
(mAGP) complex. The upper segements is composed of free lipids, some with longer 
fatty acids complementing the longer chains. Interspersed with the cell-wall proteins 
are the phosphatidylinositol mannosides (PIMs), the phthiocerol containing lipids, 
lipomannan (LM), and lipoarabinomannan (LAM).When cell walls are disrupted, for 
instance when extracted with various solvents, free lipids,proteins,LAM and PIMs are 
solubilised and the mycolic acid-arabinogalactan-peptidoglycon complex remains as 
the insoluble residue.5 
 
 
                                             Fig 1. Structure of cell wall  
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GENOME STRUCTURE 
      Mycobacterium tuberculosis H37RV was first isolated in 1905. It has 
remained pathogenic and is the most widely used strain in tuberculosis research. The 
complete genome sequence and annotation of the strain was published in 
1998.Approximately 9%of the M.tuberculosis genome consists of two related families 
of genes that have been named the PE and PPE families. These names derive from the 
presence of conserved proline glutamate(PE) or proline-proline-glutamate(PPE) 
residues near the N terminus of the predicted proteins of the family.These predicted 
protein share a conserved N terminal domain of 110 amino acids    (PE) or 180 
aminoacids (PPE)with divergent C-terminal sequence. A Subfamily of the PE family 
has been designated the PGRS proteins based on the C-terminal extension rich in a 
repetitive glycine/alanine (GA) motif. A large portion of the coding capacity of the 
M.tuberculosis genome is putatively involved with lipid biosynthesis or lipid 
degradation.4 
CHOLESTROL CATABOLISM 
             Cholesterol metabolism has been studied extensively because of its possible 
therapeutic application in Tuberculosis (TB) infection. It has been shown numerous 
times that TB infections require cholesterol for virulence in vivo, because 
Mycobacterium tuberculosis (MTB), the causative agent, utilizes cholesterol as an 
electron and carbon source during infection.6 
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PATHOPHYSILOGY OF M.TUBERCULOSIS 
             Mycobacterium tuberculosis is spread by small airborne droplets, called 
droplet nuclei. Once inhaled, infectious droplets settle throughout the airways. The 
majority of the bacilli are trapped in the upper parts of the airways where the mucus-
secreting globlet cells exist. Bacteria in droplets that bypass the mucociliary system 
and reach the alveoli are quickly surrounded and engulfed by alveolar spaces. The 
Mycobacterium lipoarabinomannan is a key ligand for a macrophage receptor.The 
complement of C3 bind to the cell wall and enhance recognition of the mycobacteria 
by macrophages. Opsonization by C3is rapid, even in the air spaces of a host with no 
previous exposure to M.tuberculosis. After being ingested by the macrophages, the 
mycobacteria continue to multiply slowly, with bacterial cell division occurring every 
25 to 32 hours. Regardless of whether the infection becomes controlled or progress, 
initial development involes protection of proteolytic enzymes and cytokines by 
macrophages in an attempt to degrade the bacteria. Released cytokinins attract T 
lymphocytes to the site, the cells that constitute cell-mediated immunity.Macrophages 
then presents mycobacterial antigen on the surface to the T cells.This initial immune 
process continues for 2 to 12 weeks;the microorganisms continue to grow until they 
reach the sufficient numbers to fully elicit the cell-mediated immune response, which 
can be detected by skin test. For persons with intact cell mediated immunity, the next 
defensive step is formulation of granulomas around the M.tuberculosis organism. 
These nodular-type lesions form an accumulation of activated T lymphocytes and 
macrophages, which creates a microenvironment that limites replication and the 
spread of the mycobacteria. M.tuberculosis organism can change their phenotypic 
expression, such as protein regulation, to enhance survival. By 2 or 3 weeks, the 
necrotic environment resembles soft cheese, often referred to caseous necrosis, and is 
characterized by low oxygen levels, low PH and limited nutrients. M.tuberculosis 
requires oxygen to grow. Ziehl-neelsen or acid-fasting staining is used.7 
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Fig. 2. Pathophysiology of M.Tuberculosis 
 
Introduction 
 
Department of pharmaceutical chemistry. Page 9 
 
MEDICINAL CHEMISTRY 
In the so called pre-scientific period, natural products having a history as folk 
remedies were in use, but little of the drug therapy of today is based on these 
remedies. Some of natural products currently used either themselves or as derivatives, 
were often used originally for other purpose, such as arrow poisons, part of religious 
or other rituals, or even cosmetics. Examples of such products include opium, 
belladonna, cinchona bark, ergot, curare, nutmeg, Calabar bean, foxglove and squill. 
              Development of drug therapy could not progress until knowledge of anatomy 
and physiology had reached the status of science. The empiric observation of Harvey 
and Sydenham were of great importance to this development in the seventeenth 
century. The work of magendie (1783-1855), an instructor of anatomy in Paris, 
probably represents the earliest application of the experimental medicine. 
             Following the French revolution, the study and classification of disease made 
considerable progress. Ineffective remedies were recognized and discarded. In 
Germany, much of the drug discovery in the nineteenth century resulted from the 
investigation in the chemical industries mainly concerned with dyes. It was not until 
the twentieth century, that the search for new drugs entities or classes took place in 
university laboratories. 
The concept of the drug-receptor interaction has undergone much 
modification from 1960s to 1990s.The use of computer graphics to portray drug-
receptor interaction has also been a notable interaction has been a notable 
development of the decade. 
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              The approaches to practice of Medicinal Chemistry has developed from an 
empiric one involving organic synthesis of new compounds, based  largely on 
modification of structure of known activity, to one that is more logical and less 
intuitive is mostly because of advancement in Molecular Biology, Pharmacology, and 
Enzymology.8 
            The primary objective of medicinal chemistry is to design and discover new 
compounds that are suitable for use as drugs.9                 
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ENZYME PROFILE 
Resistance against currently used Antitubercular therapeutics increasingly 
undermines efforts to contain the worldwide tuberculosis (TB) epidemic. Recently, 
benzothiazinone (BTZ) inhibitors have shown nanomolar potency against both drug-
susceptible and multidrug-resistant strains of the tubercle bacillus. However, their 
proposed mode of action is lacking structural evidence. The crystal structure of the 
BTZ target, FAD-containing oxido-reductase Mycobacterium tuberculosis DprE1, 
which is essential for viability. 
Different crystal forms of ligand-free DprE1 reveal considerable levels of 
structural flexibility of two surface loops that seem to govern accessibility of the 
active site. Structures of complexes with the BTZ-derived nitroso derivative CT325 
reveal the mode of inhibitor binding.  
More recently nitro-benzothiazinone (BTZs) have emerged as a promising 
class of inhibitors, effective against both drug-susceptible and MDR/XDR strains of 
Mycobacterium tuberculosis at significantly lower minimum inhibitory concentrations 
(MICs) than either isoniazid or Rifampicin, in combination with reduced toxicity.  
Biochemical studies showed that rv3790 and the neighboring gene rv3791 
code for proteins that act in concert to catalyze the epimerization of 
decaprenylphosphoryl ribose (DPR) to decaprenylphosphoryl arabinose (DPA) a 
precursor for arabinan synthesis without which a complete mycobacterial cell wall 
cannot be produced.  
DPA is the sole known donor substrate for a series of membrane-embedded 
Arabinosyl transferases, including the Ethambutol targets EmbC,  EmbA,  and EmbB 
(9). Essentiality of DPA supply and lack of alternative synthetic pathways position 
DprE1, which is highly conserved in mycobacteria, and DprE2 at a critical 
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intersection of cell wall biosynthesis. A motion confirmed by transposon mutagenesis. 
This situation has led DprE1as a magic drug target.10          
 
 
 
 
                                   
Fig 3.  DprE1 enzyme 
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General annotation11 
Table. 1 
Gene name dprE1 
Rv number Rv3790 
Type CDS 
Function 
Together dprE2(Rv3791,catalyzes epimerization of 
decarprenyl phosphoryl ribose 
(DPA) to decaprenyl phosphoryl arabinose (DPA) in arabinan 
synthesis. 
Product Decaprenylphosphoryl-beta-D-ribose 2’-epimerase-1 
Molecular mass 50163.2 
Isoelecric point 7.769 
Gene length(bp) 1386 
Protein length 461 
Location(kb) 4235.78 
Functional category Lipid metabolism 
Proteomics 
Identified in the membrane fraction of M.tuberculosis H37Rv 
using ID-SDS-PAGE and uLC-MS/MS(see Gu et al.,2003). 
Identified in the membrane fraction of M.tuberculosis H37Rv 
using 2DLC/MS (see Mawuenyega et al., 2005). 
Identified by mass spectroscopy in triton X-114 extracts of 
M.tuberculosis H37Rv(see Malen et al.,2010).Identified by 
mass spectroscopy in the membrane protein fraction and 
whole cell lysates of M.tuberculosis H37Rv but not the culture 
filtrate(See de  souza et al.,2011).Translation start site 
supported by proteomics data(See kelkar et al.,2011) 
Mutation 
Essential gene by Himar-based transposon mutagenesis 
inH37Rv strain(See Sassetti et al.,2003).Essential gene for in 
vitro growth of H37Rv, by sequencing of  Himar-based 
transposon mutagenesis (See Griffin et al.,2011) 
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DRUG DESIGN PROFILE 
 
The phrase "drug design" is to some extent a misnomer.12 what is really meant 
by drug design is ligand design (i.e., design of a small molecule that will bind tightly 
to its target). Drug design involves the design of small molecules that are 
complementary in shape and charge to the bimolecular target with which they interact 
and therefore will bind to it. Drug design is sometimes referred to as rational drug 
design or more simply rational design is the inventive process of finding new 
medications based on the knowledge of a biological target. The drug is most 
commonly an organic small molecule that activates or inhibits the function of a 
biomolecule such as a protein, which in turn results in a therapeutic benefit. 
There are two major types of drug design. The first is referred to as ligand-based drug 
design and the second, structure-based drug design.12  
TYPES OF DRUG DESIGN  
LIGAND BASED DRUG DESIGN 
Ligand-based drug design or indirect drug design relies on knowledge of other 
molecules that bind to the biological target of interest. These other molecules may be 
used to derive a pharmacophore model that defines the minimum necessary structural 
characteristics a molecule must possess in order to bind to the target. In other words, a 
model of the biological target may be built based on the knowledge of what binds to 
it, and this model in turn may be used to design new molecular entities that interact 
with the target. Alternatively, a quantitive structure-activity relationship (QSAR), in 
which a correlation between calculated properties of molecules and their 
experimentally determined biological activity, may be derived. These QSAR 
relationships in turn may be used to predict the activity of new analogs. 12 
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Fig. 4 
 
STRUCTURE BASED DRUG DESIGN 
Structure based drug design or direct design relies on knowledge of the three 
dimensional structure of the biological target obtained through methods such as X-ray 
crystallography or NMR spectroscopy. If an experimental structure of a target is not 
available, it may be possible to create a homology model of the target based on the 
experimental structure of a related protein. Using the structure of the biological target, 
drugs that are predicted to bind with high affinity and selectivity to the target may be 
designed using interactive graphics and the intuition of medicinal chemist. Current 
methods for structure based drug design can divided roughly into two categories. The 
first category is about finding ligand for a given receptor, which is usually referred as 
database searching. In this case, a large number of potential ligand molecules are 
screened to find those fitting the binding pocket of the receptor. The key advantage of 
database searching is that it saves synthetic effort to obtain new lead compounds. 
Another category of structure based drug design methods is about building ligand, 
which is usually referred as receptor-based drug design. In this case, ligand molecules 
are built up within the constraints of the binding pocket by assembling small pieces in 
a stepwise manner. These pieces can be either individual atoms or molecular 
fragments.12                        
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Fig. 5 
 
ACTIVE SITE IDENTIFICATION  
Active site identification is the first step. It analyzes the protein to find the binding 
pocket, derives key interaction sites within the binding pocket, and then prepares the 
necessary data for ligand fragment link. Both ligand and protein atoms need to be 
classified and their atomic properties should be defined, basically, into four atomic 
types;  
 Hydrophobic atom: All carbons in hydrocarbon chains or in aromatic groups.  
 H-bond donor: Oxygen and nitrogen atoms bonded to hydrogen atom [s].  
 H-bond acceptor: Oxygen and sp2 or sp hybridized nitrogen atoms with lone 
electron pair [s].  
 Polar atom: Oxygen and nitrogen atoms that are neither H- bond donor nor H- 
bond acceptor, sulfur, phosphorus, halogen, metal, and carbon atoms bonded 
to hetero-atom(13)   
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SCORING METHOD  
Structure-based drug design attempts to use the structure of proteins as a basis 
for designing new ligands by applying accepted principles of molecular recognition. 
The basic assumption underlying structure-based drug design is that a good ligand 
molecule should bind tightly to its target.12 
SCREENING AND DESIGN 
The process of finding a new small molecule (ligand) against a chosen target 
for a particular disease usually involves high-throughput screening (HTS).  
The structure-activity relationship (SAR) is to improve certain features of the lead 
compound:  
 Increase activity against the chosen target  
 Reduce activity against unrelated targets  
 Improve the drug likeness or ADME properties of the molecule.  
This process will require several iterative screening runs, during which, it is 
hoped, that properties of the new molecular entities will improve, and allow the 
favored compounds to go forward to in vitro and in vivo testing for activity in the 
disease model of choice. A range of parameters can be used to assess the quality of a 
compound, or a series of compounds, as proposed in the Lipinski's Rule of Five. Such 
parameters include calculated properties such as clog P to estimate lipophilicity, 
molecular weight, polar surface area and measured properties, such as potency, in-
vitro measurement of enzymatic clearance etc. Some descriptors such as ligand 
efficiency (LE) and lipophilic efficiency (LiPE) combine such parameters to assess 
drug likeness.Other methods, such as virtual high through put screening, where 
screening is done using computer-generated models and attempting to "dock" virtual 
libraries to a target, are also often used.  
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Another important method for drug discovery is FBLD drug design, whereby 
the       biological and physical properties of the target are studied, and a prediction is 
made on the sorts of small molecules that might (e.g.) fit into an active site. The 
fragment-based lead discovery (FBLD), novel pharmacophore can emerge very 
rapidly from these exercises. In general, computer-aided drug design is often used to 
try to improve the potency and properties of new drug leads.12 
COMPUTER-AIDED DRUG DESIGN 
Computer-aided drug design uses computational chemistry to discover, 
enhance, or study drugs and related biologically active molecules. Molecular 
mechanics or molecular dynamics are most often used to predict the conformation of 
the small molecule and to model conformational changes in the biological target that 
may occur when the small molecule binds to it.  
Molecular mechanics methods may also be used to provide semi-quantitative 
prediction of the binding affinity. Also, knowledge-based scoring function may be 
used to provide binding affinity estimates.  
Drug design with the help of computers may be used at any of the following stages of 
drug discovery: 12 
 Hit identification using virtual screening (structure- or ligand-based design)  
 Hit-to-lead optimization of affinity and selectivity (structure-based design, 
QSAR, etc.)  
 Lead optimization: optimization of other pharmacokinetic properties while 
maintaining affinity. 
In order to overcome the insufficient prediction of binding affinity 
calculated by recent scoring functions, the protein-ligand interaction and a 
compound’s 3D structure information are used for analysis.12 
  
Introduction 
 
Department of pharmaceutical chemistry. Page 19 
 
MOLECULAR PROPERTY PREDICTION 
All the data set molecules were subjected to the toxicity risk assessment by 
using Osiris program, which is available online. The OSIRIS property Explorer 
shown in this page is an integral part of Actelion's in house substance registration 
system. It allows drawing chemical structures and also calculates various drug 
relevant properties whenever a structure is valid. Prediction results are color coded in 
which the red colour shows high risks with undesired effects like mutagenicity or a 
poor intestinal absorption and green colour indicates drug-conform behave  
Molecular property prediction includes 
 Toxicity risk assessment  
 Clog prediction  
 Solubility prediction  
 Molecular weight  
 Drug linkers prediction  
 Drug linkers  
TOXICITY RISK ASSESSMENT 
On drawing a structure the toxicity risk predictor will start looking for 
potential toxicity risks as long as the currently drawn structure is a valid chemical 
entity. Toxicity risk alerts are an indication that the drawn structure may be harmful 
concerning the risk category specified. The prediction process relies on a 
precomputed set of structural fragment that give rise to toxicity alerts in case they are 
encountered in the structure currently drawn. These fragment lists were created by 
rigorously shreddering all compounds of the RTECS database known to be active in a 
certain toxicity class like mutagenicity, Tumorigenicity, Irritating effects and 
Reproductive effects. (13) 
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Clog P  PREDICTION  
The logP value of a compound, which is the logarithm of its partition 
coefficient between n- octanol and water log (octanol/water), is a well-established 
measure of the compound's hydrophilicity. Low hydrophilicities and therefore high 
logP values cause poor absorption or permeation. clogP value must not be greater than 
5.0 for permeability. (13) 
SOLUBILITY PREDICTION 
The aqueous solubility of a compound significantly affects its absorption and 
distribution characteristics. Typically, a low solubility goes along with a bad 
absorption and therefore the general aim is to avoid poorly soluble compounds.(13)  
MOLECULAR WEIGHT 
Optimizing compounds for high activity on a biological target almost often 
goes along with increased molecular weights. However, compounds with higher 
weights are less likely to be absorbed and therefore to ever reach the place of action. 
Thus, trying to keep molecular weights as low as possible should be the desire of 
every drug forger. (13) 
DRUG LIKENESS 
Drug likeness is a qualitative concept used in drug design for how "drug like" 
a substance is with respect to factors like bioavailability. It is estimated from the 
molecular structure before the substance is even synthesized and tested. A drug like 
molecule has properties such as: Solubility in both water and fat, as an orally 
administered drug needs to pass through the intestinal lining after it is consumed, 
carried in aqueous blood and penetrate the lipid cellular membrane to reach the inside 
of a cell. A model compound for the lipophilic cellular membrane is octanol (a 
lipophilic hydrocarbon), so the logarithm of the octanol/water partition coefficient, 
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known as LogP, is used to predict the solubility of a potential oral drug. This 
coefficient can be experimentally measured or predicted computationally, in which 
case it is sometimes called "clogP". (13) 
The logP value of a compound, which is the logarithm of its partition 
coefficient between n- octanol and water log (octanol/water), is a well-established 
measure of the compound's hydrophilicity. Low hydrophilicities and therefore high 
logP values cause poor absorption or permeation. clogP value must not be greater than 
5.0 for permeability. (13) 
SOLUBILITY PREDICTION 
The aqueous solubility of a compound significantly affects its absorption and 
distribution characteristics. Typically, a low solubility goes along with a bad 
absorption and therefore the general aim is to avoid poorly soluble compounds. (13)  
MOLECULAR WEIGHT  
Optimizing compounds for high activity on a biological target almost often 
goes along with increased molecular weights. However, compounds with higher 
weights are less likely to be absorbed and therefore to ever reach the place of action. 
Thus, trying to keep molecular weights as low as possible should be the desire of 
every drug forger. (13) 
DRUG LIKENESS 
Drug likeness is a qualitative concept used in drug design for how "drug like" 
a substance is with respect to factors like bioavailability. It is estimated from the 
molecular structure before the substance is even synthesized and tested. A drug like 
molecule has properties such as: Solubility in both water and fat, as an orally 
administered drug needs to pass through the intestinal lining after it is consumed, 
carried in aqueous blood and penetrate the lipid cellular membrane to reach the inside 
Introduction 
 
Department of pharmaceutical chemistry. Page 22 
 
of a cell. A model compound for the lipophilic cellular membrane is octanol (a 
lipophilic hydrocarbon), so the logarithm of the octanol/water partition coefficient, 
known as LogP, is used to predict the solubility of a potential oral drug. This 
coefficient can be experimentally measured or predicted computationally, in which 
case it is sometimes called "clogP". (13)  
LIPINSKI’S RULE OF FIVE(14-15) 
Lipinski's rule of five also known as the Pfizer's rule of five or simply the Rule 
of five (RO5) is to evaluate drug likeness or determine if a chemical compound with a 
certain pharmacological or biological activity has properties that would make it a 
likely orally active drug in humans. The rule was formulated by Christopher A. 
Lipinski in 1997.  
The rule describes molecular properties important for a drug’s 
pharmacokinetics in the human body, including their absorption, distribution, 
metabolism, and excretion ("ADME"). However, the rule does not predict if a 
compound is pharmacologically active.  
Lipinski's rule states that, in general, an orally active drug has no more than one 
violation of the following criteria:  
 Not more than 5 hydrogen bond donors (nitrogen or oxygen atoms with one or 
more hydrogen atoms). 
  Not more than 10 hydrogen bond acceptors (nitrogen or oxygen atoms) 
 A molecular mass less than 500 Daltons.  
  An octanol-water partition coefficient log P not greater than 5.  
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BIOLOGICAL ACTIVITY OF BENZIMIDAZOLE 
N
H
N
 
 Benzimidazole is the heterocyclic compound formed from benzene and 
imidazole ring wide interest because of their diverse biological activity and clinical 
applications, they are remarkably effective compounds both with respect to their 
inhibitory activity and their favorable selectivity ratio. Reported nucleus is a 
constituent of vitamin-B12. It occurs as white crystals. It is used as muscle 
relaxant.(16) 
SYNONYMS(17)    
 Benziminazole,  
 3-benzodiazole, 
 Azindole, 
 Benzoglyoxaline,                    
 3-azaindole,  
 1,3-diazaindene  
 Meting point    170-17200C  
 
BIOLOGICAL ACTIVITY(18) 
 Antimicrobial,   
 Antiviral, 
 Antidiabetic, 
 Antiulcer,  
 Anticancer. 
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Anti-ulcer drugs 
These are the drugs which inhibits both basal and stimulated gastric acid   
secretion. Some drugs containing benzimidazole nucleus are Pantoprazole, 
Rabeprazole, Lansoprazole, Omeprazole etc
 
 
Anti-psychotic agents
           In psychosis thinking of patient becomes illogical, bizarre and loosely                
organized. Patient has difficulty in understanding reality and their own conditions. 
Some drugs containing benzimidazole nucleus are droperidol, pimozide, and
benperidol.            
Ex. Droperidol 
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 Ex. Omeprazole 
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Anthelmintic 
           These are the drugs that either kill or expel infesting helminthes. Some drugs 
containing benzimidazole nucleus are Thibendazole, Mebendazole, and Albendazole 
etc.  Ex. Mebendazole 
 
 
 
Anti-protozoal agents
               These are the drugs which are used to treat the amoebiasis caused by 
E.histolytica. They exert cytotoxicity by damaging DNA and result in DNA helix 
destabilization strand breakage. The antiprotozoal drugs containing imi
are metronidazole, benznidazole. 
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Ex. Metronidazole 
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Antifungal 
These are the drugs used for superficial and deep fungal infections. Fungal 
infections are termed mycoses and in divided in to superficial infections (skin, nails, 
and scalp) and systemic infections (deeper tissues and organs) some conditions are 
blastomycosis, histoplasmosis, candidiasis, coccibiomycosis etc. superficial fungal 
infections can be classified in to the 
antifungal agents containing imidazole nucleus are Clotriamazole, Miconazole, 
Ketoconazole.(18). Ex. 
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dermatomycoses and candidiasis
Ketaconazole 
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2. REVIEW OF LITERATURE 
 
The Purpose of Literature Review is to: 
 Establish a theoretical frame work for a topic /subject area 
 Define key terms and terminology  
 Identify studies, models, case studies etc supporting a topic  
 Define /establish an area of study  
The review on following works provided basic information about the target 
enzyme, DprE1 and its function 
Sarah M. Batt., et al., (2012) Structural basis of inhibition of Mycobacterium 
tuberculosis DprE1 by benzothiazinone  inhibitors .(10)  
Maria Loreto Incandela., et.al.,(2013) reported that DprE1, a new taxonomic marker 
in mycobacteria.(19) 
The following works throws a light upon the various genomic aspects of 
M.tuberculosis and also various targets intended for drug action: 
Donald R Ronning., et al., (2012) Targeting the mycobacterial envelope for 
tuberculosis drug development.(20) 
 Sarala Menon., et al., (2012), studied the Drug resistance profiles of Mycobacterium 
tuberculosis isolates to first line anti-tuberculous drugs.(21) 
 P.Mudassar., et al., (2011) Had a Brief review on Multi Drug resistant 
Mycobacterium tuberculosis.(22) 
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Christian Lienhardt., et al., (2010) Had a review on New drugs and new regimens for 
the treatment of tuberculosis: review of the drug development pipeline and 
implications for national programmes.(23)  
Sarah L. Kinnings., et al., (2010), reviewed the Mycobacterium tuberculosis Drugome 
and Its Polypharmacological Implications.(24) 
The review on following works provided ideas for synthesis of the desired 
chemical entities: 
Elina R. Marinho.,et al The reaction of o-phenylenediamine with ethoxymethylene 
compounds and aromatic aldehyde,( 2009).(25)    
A. M. Soliman, Synthesis and biological activity of dihydroimidazole and 3,4-
dihydrobenzo[4,5]imidazo[1,2-a][1,3,5]triazins,  (2012) . (26)    
 Shaaban K Mohamed, Eco-Friendly Synthesis of Pyrimidine and 
Dihydropyrimidinone Derivatives under Solvent Free Condition and their Anti-
microbial Activity, (2013) (27) 
Babu K,Synthesis of novel benzimidazole derivatives.(28)    
                             
N
H
N
NH
NH
NH2
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SHIFF BASE:     
Zhaoqi Yang, Pinhua Sun, Compare of three ways of synthesis of simple Schiff base, 
2006.(29)            
Marcus Vinı´cius Nora de Souza ,carried out Synthesis and antimycobacterial 
activity of (E)-N0-(monosubstituted-benzylidene) isonicotino 
hydrazide derivatives,2008.(30) 
 
 
 A.Mobinikhaled, et al.,An efficient   synthesis  of  Schiff bases containing 
Benzimidazole   moiety catalyzed by transition metal nitrates,(2010).(31) 
 
 Mostafa M. H. Khalil,et al., Synthesis and characterization of a novel schiff base 
metal complexes and their application in determination of iron in different types of 
natural water, 2012.(32)         
 
Sandeep Miglani, et al., The rapid synthesis of schiff-bases without solvent under 
microwave irradiation and their antimicrobial activity, (2012).(33) 
R
O
NH2
R
+
N
R
R
-H20
 
  
Review literature 
 
Department of Pharmaceutical Chemistry Page 30 
 
K. Brodowska,et al., Schiff bases – interesting range of applications in various fields 
of science,(2014).(34)      
 
 
Panneer Selvam .T et al., synthesized a novel series of 2-substituted benzimidazole 
derivatives were synthesized and characterized.(35) 
 
The following literatures were surveyed in depth to provide supporting data for 
the drug design study  
 
LaurieAT.,et.al.,(2005) Q site finder”on energy based method for the prediction of 
protein –ligand binding site” Bioinformatics,(36)  
 
http ; // www.modelling leads.ac.uk /q site finder / (37)  
 
Sanju joy ,parvathy S Nair.,et.al.,(2006) “Detailed comparison of Pro-ligdocking 
efficiency of GOLD” , a commercial package and Argus lab, a licensable freeware 
[insilico biology 6,0053 [2006] (38)        
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The review on following works revealed the basics of Alamar blue assay for 
evaluating the anti-mycobacterial action.  
 
David A. J. Moore., et al., (2008), Inter- and Intra-Assay Reproducibility of Micro 
plate Alamar Blue Assay Results for Isoniazid, Rifampicin, Ethambutol, 
Streptomycin, Ciprofloxacin, and Capreomycin Drug Susceptibility Testing 
ocobacterium tuberculosis. (39) 
 
Todd P. Primm., et al., (2007), Recent Advances in Methodologies for the Discovery 
of Antimycobacterial Drugs.(40) 
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3. AIM AND OBJECTIVES 
 
With the ongoing progress in protein crystallography and NMR, structure-
based drug design is gaining increasing importance in the search for new drugs. 
Modeling starts from the 3D structure of a target protein in order to construct 
molecules which are complementary to a binding site, in their geometry as well as in 
the pattern of their physicochemical properties around the molecules The present 
study relates to the synthesis of various aryl carboxylic acid derivatives and 
subsequent screening for their anti-tubercular activity. Due to several toxic effects of 
isoniazid, attempts were made to eliminate the toxicophore and substituting with a 
group contributing to the anti-tubercular action. This work also aims the same motive 
and the compounds were synthesized according to the developed and valid synthetic 
route.  
DOCKING  
A chemical data base consisting 500 compounds of various scaffolds had been 
sketched and docked against the protein target of DPrE1. Based upon the docking 
score the 50 compounds were selected. For further modifications /derivatisation in 
order to achieve improved binding affinity and then once again docked against the 
same target.  
Based upon the docking score the first 20 compounds with diverse scaffolds 
were selected. From these 20 compounds 5 top ranked compounds were selected 
based upon the Insilco toxicity prediction and then synthetic feasibility.                                                
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The compounds are as follows: 
  COMPOUND1: 
N-1H-benzimidazol-2-yl-N'-{(Z)-[4-(dimethylamino)phenyl]methylidene} guanidine 
COMPOUND2: 
N-1H-benzimidazol-2-yl-N'-[(Z)-(4-hydroxyphenyl)methylidene]guanidine 
COMPOUND3:  
N-1H-benzimidazol-2-yl-N'-[(Z)-(2,4-dichlorophenyl)methylidene]guanidine 
CHARACTERIZATION 
  The above compounds will be characterized by using infrared spectroscopy, 
nuclear magnetic spectroscopy and mass spectroscopy.  
BIOLOGICAL EVALUATION  
The synthesized compounds will be screened for their anti-tubercular activity 
by various in-vitro methods.  
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4.METERIALS AND METHODS 
I) DOCKING  
1) MOLECULAR DOCKING BY ARGUS LAB SOFTWARE 
Docking analysis of synthesized compounds i.e. ligands will be carried out by 
Argus labR docking software. Docking allows the medicinal chemist to virtually 
screen a set of compounds and predict the strongest binding capacity based on various 
scoring function. It explores ways in which two molecules such as ligand and receptor 
(protein) fit together and docks to each other well. The molecule binding to a receptor 
inhibits its function and thus acts as drug.  
Argus lab 4.0 distributed freely for windows platforms by planaria software. 
It is an introductory molecular modeling package with academics. Argus docking 
engine implementry in Argus lab approximates an exhaustive search method which is 
similar to DOCK and GLIDE. Flexible ligand docking is possible with Argus lab, 
where the ligand is described as torsion tree and grids are constructed that overlay the 
binding site. The accuracy of the Argus lab docking algorithm takes into account, the 
key features such as the nature of the binding site and the number of rotatable bonds 
to the ligand.  
Molegro molecular viewer 
Molegro molecular viewer is an application which helps in analyzing the 
energies and interaction of the binding site.  
Q-site finder 
Q-site finder is an energy-based method for protein-ligand binding site 
prediction. During prediction we use the crystal structures of macromolecules 
(receptor) with small substrates (pdb ID). Identifying the location of binding sites on a 
protein is of fundamental importance for a range of applications including molecular 
docking. It uses the interaction energy between the protein and a simple vanderwaals 
probe to locate energetically favorable binding sites.  
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A. PREPARATION OF PROTEIN:  
STEP 1                
 Enter protein pdb ID (3VAE) in the protein data bank in the protein data bank. 
 Go to download files and select pdb as text file.  
 Save the downloaded pdb text file to desktop.  
STEP 2 
 Open Argus lab file → open → Import pdb file from the desktop.  
 3D structure of the protein will appear in the workspace of Argus lab.  
 Left side of the screen shows molecular tree view.  
 Open pdb → open ‘Residues’ → open ‘Misc’.  
 From ‘Misc’ delete the inhibitor and hetero residues, do not delete cofactor  
 Open water press shift, select all water molecules and delete.  
 Add hydrogen atoms.  
 Go to calculation on toolbar → energy by UFF method → start.  
 Save the prepared protein as *.agl file format in the desktop.    
B. IDENTIFICATION/ SELECTION OF ACTIVE SITE 
STEP 1 
  Q-site finder was opened through online.  
 The pdb format of the protein was imported.  
 Found all the active site and make a list out of the common amino acid 
residues.  
 STEP 2 
  residues → open amino acids was opened.  
  Control was selected and select the amino acids which were listed from the Q-
site finder.  
 Make sure that all the amino acid residues listed are selected.  
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 Right click on the mouse → make a group from the selected residues → give 
name → Binding site → OK.  
C. PREPARATION OF LIGANDS 
 Drawn the structure from chem. Sketch and save as MDL mol format.  
  The ligand wae imported into workspace of Argus lab.  
 Clean geometry → clean hybridization. Select the ligand; right click on the 
mouse → make a group from the residues → give name→ ligand→ OK.  
  The ligand was selected; right click on the mouse → make a group from the 
residues → give name→ ligand→ OK. 
D. DOCKING PARAMETER :  
 Calculation was selected from the toolbar → Dock a ligand.  
 ‘Argus Dock’ as the Docking engine. 
 ‘Dock’ was selected as calculation type. 
 ‘Flexible’ for the ligand. 
 Ascore as the scoring function. 
 Calculation size.  
 Docking was started. 
Save the Docked protein Ligand complex as Brookhaven pdb files (*.pdb)  
E. VISUALIZATION/INTERPRETATION OF DOCKING :  
 Molegro molecular viewer will help in analyzing the energies and interaction 
of the binding.  
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II) REACTANT PROFILE(41) 
O-PHENYLENE DIAMINE: 
                            
NH2
NH2
 
 
Molecular Formula                :C6H 8N2 
Molecular Weight                  :108.14 
Description                            : brown in colour 
Melting point                          :102-1040C 
 
CYANOQUANIDINE: 
                          
NH2
NH
NH
N
 
Molecular Formula                :C2H 4N2 
Molecular Weight                  :84.08 
Description                            : White crystals 
Melting  point                          :2090C 
 
4-HYDROXYL BENZALDEHYDE: 
                      
OH
O
 
Molecular Formula                :C7H 6O2 
Molecular Weight                  :121.12 
Description                            : Light yellowish to light brown 
Melting point                          :1910C 
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N,N’ DIMETHYL BENZALDEHYDE: 
 
                                
N
O
CH3CH3
 
 
Molecular Formula                :C 9H 11NO 
Molecular Weight                  :149.19 
Description                            : White crystalline powder 
Melting point                          :72-750C 
 
 
2,4 DICHLORO BENZALDEHYDE: 
 
                                  
O
Cl
Cl
 
 
Molecular Formula                :C7H 4Cl 2O 
Molecular Weight                  :175.01 
Description                            : White crystalline powder 
Melting point                          :2330 C 
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3.SYNTHETIC METHODOLOGY                     
STEP1                
Synthesis of 2-benzimidazolylguanidine(26) 
  A mixture of o-phenylenediamine (100 mmol), cyanoguanidine (100 mmol) 
and concentrated Hydrochloric acid (20ml) in water (200 ml) is heated under reflux 
for 3 hrs. The reaction mixture is cooled at 0°C and KOH (10%; 50 ml) was added 
slowly. The precipitates of 2-guanidinobenzimidazole is collected by filtration, 
washed with water, dried and recrystallized by ethanol.  
NH2
NH2
+
N
H
N
NH
NH2
NHNH
NH2
NH
N
HCl, reflux 3 h
10 %KOH
 
 
STEP 2  
Synthesis of Schiff base(30) 
An equimolar quantity of 2-benzimidazoylguanidine and substituted aromatic 
aldehyde is refluxed for 10-15 hours in 20ml ethanol. Completion of reaction is 
monitored by TLC. After completion of the reaction the content is poured into ice 
cold water. The precipitate collected by filtration, washed with water and dried. 
Recrystallization is carried out by ethanol. 
N
H
N
NH
NH
NH2
+
O
R
Reflux for 10-15 hrs
Ethanol
NH
N
NH
N
NH
R
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SYNTHESIS OF COMPOUNDS: 
 
 
 
 
2-benzimidazolylguanidine reacts with 
                                
1. N,N’ dimethylaminobenzaldehyde  
2. p-hydroxybenzaldehyde 
3. Dichlorobenzaldehyde 
  
Materials and Methods 
 
Department of Pharmaceutical Chemistry Page 41 
 
JUSTIFICATION OF PURITY:   
A.THIN LAYER CHROMATOGRAPHY 
Precoated aluminium TLC plates are used. Solutions of the reactants and 
products are prepared by dissolving them in methanol. Stationary Phase: Precoated 
Silica Gel Plates. Mobile Phase: Chloroform: Methanol (3:2) Visualization: Iodine 
Vapors and UV chamber A single spot not corresponding to the parent compound is 
indicative. Absence of other spots justifies the purity of the product. 
B. MELTING POINT  
The melting points of synthesized compounds are determined by open tube 
capillary method with an aid of a melting point apparatus. The melting points were 
Sharp melting point are indicate the purity of the product. 
CHARACTERISATION STUDIES  
A. INFRA RED (IR) SPECTROSCOPY  
The recrystallised compounds are subjected to IR spectral analysis for 
functional group identification using KBr pellet method. Stretching and bending 
vibrations for the new functional are indicated. Absence of the vibrational bands for 
the parent functional group is ensured.  
B. NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROSCOPY  
1H NMR spectra are recorded on samples are prepared by dissolving a minute 
quantity of pure compounds in DMSO. Chemical shifts are reported in parts per 
million (ppm)  
C. MASS SPECTROSCOPY:  
Mass Spectra is recorded on Shimadzu HPLC-MS using Electron Spray 
Ionization Technique and was quantified using La Solutions Software 7.0, Samples 
are prepared by dissolving a minute quantity of pure compounds in methanol. The 
fragmentation patterns are reported in m/z values. 
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MICROBIOLOGICAL ASSAY:  
Microbial assays or microbiological assays is a type of bioassay and are 
designed to analyze the compounds or substances which have effect on micro-
organisms. Microbiological assay is defined as the determination or estimation of 
concentration or potency of an antibiotic by means of measuring and comparing the 
area of zone of inhibition or turbidity produced by test substance with that of standard 
over a suitable microbe under standard conditions. So as definition says the 
hypothesis is that when an antibiotic is administered, there is inhibition in the growth 
of microbe as indicated by decrease in area of zone of microbial colony on nutrition 
media or decrease in turbidity due to decrease in microbial concentration.(43,44)  
TYPES OF MICROBIOLOGICAL ASSAY:  
REDOX BASED METHODS:  
Micro plate Alamar blue assay. Resazurin Microtiter Assay, REMA, or Micro 
dilution Resazurin Assay, MRA. Tetrazolium Dyes, Tetrazolium Microplate Assay, 
TEMA.  
REPORTER GENE-BASED METHODS:  
Green Fluorescent Protein Micro plate Assay, GFPMA; Luciferase Assays; 
Beta-Galactosidase Assays.  
OTHER METHODS: BACTEC 460 TB 
Nitrate Reductase Assay, NRA; Disk Diffusion; Visual Micro broth, or Broth 
Micro dilution; Malachite Green; STC Agar; Flow Cytometr 
MICROPLATE ALAMAR BLUE ASSAY:  
MABA is clearly the standard in the field for HTS of compounds against 
mycobacteria, and is the most widely cited. The primary reference for the method is 
Collins and Franzblau in 1997. In that study, MABA was effective with MTB H37Rv, 
H37Ra and M. avium strain ATCC 25291, a relatively virulent isolate. MABA is 
reliable with clinical isolates of MTB and MIC. MABA has also been applied to M. 
kansasii and M. malmoense, as well as M. leprae. In addition to screening and 
sensitivity applications, MABA has also been used in patient treatment follow-up. 
MABA can operate in simple colorimetric mode with visual reading (blue to pink 
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change indicates viability,with the MIC recorded as the lowest compound 
concentration in wells which remain blue). Newly synthesized product are assayed in 
vitro for anti-tubercular activity. Evaluation of the products for their in vitro 
antitubercular activity against Mycobacterium Tuberculosis H37Rv using 
MicroplateAlamar Blue Assay (MABA) biological test is done. This methodology is 
nontoxic, uses a thermally-stable reagent and shows good correlation with 
proportional and BACTEC radiometric methods.(40,42)  
Anti-TB activity using Alamar Blue Dye:  
1. The anti-mycobacterial activity of compound are assessed against M. 
tuberculosis using micro plate Alamar Blue assay (MABA).  
2. This methodology is non-toxic, uses a thermally stable reagent and shows 
good correlation with proportional and BACTEC radiometric method.  
3. Briefly, 200µl of sterile deionized water is added to all outer perimeter wells 
of sterile 96 wells plate to minimized evaporation of medium in the test wells 
during incubation.  
4. The 96 wells plate receive 100 µl of the Middle brook 7H9 broth and serial 
dilutions of compounds were made directly on plate.  
5. The final drug concentrations tested are 100 to 0.8 µg/ml.  
6. Plates were covered and sealed with par film and incubated at 37ºC for five 
days.  
7. After this time, 25µl of freshly prepared 1:1 mixture of Alamar Blue reagent 
and 10% tween 80 was added to the plate and incubated for 24 hrs.  
8. A blue color in the well was interpreted as no bacterial growth, and pink color 
was scored as growth.  
9. The MIC was defined as lowest drug concentration which prevented the color 
change from blue to pink.(42,43)  
 RESULTS  
AND 
DISCUSSION 
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RESULTS AND DISCUSSION 
Results of drug design 
 Two hundred molecules, which are sketched using chem sketch were docked 
against the MTB enzyme Decaprenylphosphoryl-beta-D-ribose 2’-epimerase-1by 
using Argus lab 4.0.1 software. The molecules with best docking score and good 
interactions were selected and synthesized. 
 The molecules were also docked against the following targets 
1. Methoxy mycolic acid 
2. Glutamine synthetase 1 
3. Cyclopropane mycolic acid synthase 2 
Table no: 2 
Name of the target 
Docking score 
R1 R2 R3 
Decaprenylphosphoryl-beta-D-
ribose 2’-epimerase-1 
-7.62223 -8.02866 -8.52044 
Methoxy mycolic acid -6.62823 -8.029316 -7.92264 
Glutamine synthetase 1 -6.85964 -8.38081 -7.37541 
Cyclopropane mycolic acid 
synthase 2 
-8.06321 -7.36964 -8.30648 
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Interactions of the docked molecules with the enzyme Decaprenylphosphoryl-
beta-D-ribose 2’-epimerase-1. 
Table no: 3 
Sampl
e code Docking view 
 
Interactions with amino acids 
 
R1 
 
 
R2 
 
 
 
R3 
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Product profile 
Compound R1 
Physicochemical Properties of N-1H-Benzimidazol-2-Yl-N'-[(E)-(4 hydroxy 
phenyl) methylidene] Guanidine  
N
H
N
NH
NH
N
OH
 
Table no: 4 
Description Reddish brown colour solid 
Solubility Soluble in methanol,Ethanol 
Molecular Formula  C 15H 13N 5O 
HFormula Weight  279 
Composition C(64.51%) H(4.69%) N(25.07%) O(5.73%) 
Molar Refractivity  79.01 ± 0.5 cm 
Molar Volume  201.4 ± 7.0 cm3 
Parachor  560.9 ± 8.0 cm3 
Index of Refraction  1.713 ± 0.05 
Surface Tension 60.1 ± 7.0 dyne/cm 
Density  1.38 ± 0.1 g/cm3 
Polarizability 31.32 ± 0.5 10-24cm3 
Monoisotopic Mass  279.11201 Da 
Nominal Mass  279 Da 
Average Mass  279.2966 Da 
M+ 279.111461 Da 
M-  279.112559 Da 
[M+H]+ 280.119286 Da 
[M+H]-  280.120384 Da 
[M-H]+   278.103636 Da 
[M-H]-   278.104734 Da 
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Compound R2 
Physicochemical Properties of N-1H-Benzimidazol-2-Yl-N'-[(Z)-(4 dimethyl 
amino) phenyl] methylidene}Guanidine                        
N
N
H
N
NH
NH
N CH3
CH3
 
Table no: 5 
Description Orange in colour 
Solubility Soluble in methanol,Ethanol 
Molecular Formula C 17H 18N 6 
Formula Weight 306 
Composition C(66.65%) H(5.92%) N(27.43%) 
Molar Refractivity 90.96 ± 0.5 cm3 
Molar Volume 245.3 ± 7.0 cm3 
Parachor 651.6 ± 8.0 cm3 
Index of Refraction 1.663 ± 0.05   
Surface Tension 49.7 ± 7.0 dyne/cm 
Density 1.24 ± 0.1 g/cm3 
Polarizability 36.06 ± 0.5 10-24cm3 
Monoisotopic Mass 306.159295 Da 
Nominal Mass 306 Da 
Average Mass 306 Da 
M+ 306.365 Da 
M- 306.158746 Da 
[M+H]+ 307.166571 Da 
[M+H]- 307.167668 Da 
[M-H]+ 305.152018 Da 
[M-H]- 305.150921 Da 
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Compound R3 
 Physicochemical properties of  N-1H-benzimidazole-2-yl  
N’{(z)[2,4(dichloro)phenyl]methylidine} guanidine. 
                                                       
N
H
N
NH
N
NH
Cl
Cl
 
 
Table no: 6 
Description  light white in colour. 
Solubility soluble in ethanol,methanol 
Molecular Formula  C15 H 11Cl 2N5 
HFormula Weight  332 
Composition C(54.23%)H(3.34%)Cl(21.35%)N(21.08%) 
Molar Refractivity 87.35 ± 0.5 cm3 
Molar Volume 222.7 ± 7.0 cm3 
Parachor 613.0 ± 8.0 cm3 
Index of Refraction 1.713 ± 0.05 
Surface Tension 57.3 ± 7.0 dyne/cm 
Density 1.49 ± 0.1 g/cm3 
Polarizability 34.63 ± 0.5 10-24cm3 
Monoisotopic Mass 331.039151 Da 
Nominal Mass 331 Da 
Average Mass 331.1234Da 
M+ 332.1565 
M- 332.1678 
[M+H]+ 332.1498 
[M+H]- 332.1685 
[M-H]+ 332.5845 
[M+H]- 332.8796 
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CHARACTERIZATION: 
                        Newly synthesized compounds were characterized by 
• IR 
• NMR 
• GC-MS 
IR SPECTROSCOPY 
        The samples were prepared by the KBr pellet technique and spectrum obtained 
from ABB(MB 3000) spectrophotometer 
         The spectra were examined for the absence of the functional group region of 
parent compound and examined for presence of the vibrational absorption band for 
the new functional group. 
        Our reaction involves reaction between Aldehyde and amine to yield of Schiff 
bases. 
• The absorption band for aldehydes are   
                                         2800-2700cm-1 
                                         1700-1750cm-1                        
• The absorption band for amine  3400-3600 cm-1 
• The absorption of newly synthesized –C=N- is 1650-1600cm-1 
Table no: 7 
IR absorption band R1 R2 R3 
Aldehyde - - - 
Amine - - - 
-C=N- +
 
+ + 
 
(+) indicates  presence 
(-) indicates absence 
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IR SPECTRUM OF R1: 
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 IR SPECTRUM OF R2: 
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IR SPECTRUM OF R3: 
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NMR 
  1H NMR spectra are recorded on Bruker Advance III 500 MHz NMR 
spectrophotometer 
  
COMPOUND R1 
 
                                             Table no: 8 
TYPE OF PROTON NO OF PROTON DELTA(δ) NATURE OF PEAK 
-NH 3 3.4-4.1 Multiplate 
-OH 1 5.4 Singlet 
Ar-H 8 6.3-7.1 Multiplate 
 
 
N
H
N
NH
NH
N
OH
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COMPOUND R2 
 
 
Table no:9 
TYPE OF PROTON NO OF PROTON DELTA(δ) NATURE OF PEAK 
-NH 3 3.2-3.7 Multiplate 
-N(CH3)2 4 2.8-3.1 Singlet 
Ar-H 8 6.4 Singlet 
 
 
 
 
 
N
N
H
N
NH
NH
N CH3
CH3
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COMPOUND R3  
 
 
Table no:10 
TYPE OF PROTON NO OF PROTON DELTA(δ) NATURE OF PEAK 
-NH 1 2.2-2.4 Singlet 
Ar-H 7 7.8-8 Multiplate 
=CH- 1 8.2 Singlet 
 
 
 
 
 
N
H
N
NH
N
NH
Cl
Cl  
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GC-MS: 
       The molecular weight of the synthesized compounds were compared by GC-MS 
analysis. 
Table no: 11 
Compound Calculated  mass Actual Mass 
R1 279 279 
R2 306 306 
R3 332 331 
 
  
Results and Discussion 
 
Department of Pharmaceutical Sciences Page 57 
 
Compound R1: 
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Compound R2: 
   
 
 
Compound R3: 
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TOXICITY RISK ASSESSMENT 
All the data set molecules were subjected to the toxicity risk assessment by 
using Osiris program, which is available online free of cost. The OSIRIS property 
Explorer shown in this page is an integral part of Actelion's in house substance 
registration system. It allows drawing chemical structures and also calculates various 
drug relevant properties whenever a structure is valid. Prediction results are color 
coded in which the red colour shows high risks with undesired effects like 
mutagenicity or a poor intestinal absorption and green colour indicates drug-conform 
behavior.  
Molecular property prediction includes  
 Toxicity risk assessment 
 Clog P predicition 
 Solubility prediction  
 Molecular weight 
Table no: 12 
Samples R1 R2 R3 
Mutagenic + + + 
Tumorigenic + - + 
Irritant + + + 
Reproductive effective + + + 
  
(+) indicates absence of toxicity 
(-)indicates presence of toxicity 
Department of Pharmaceutical Sciences
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BIOLOGICAL SCREENING  
 
The synthesized compounds were screened for their in-vitro anti 
mycobacterial activity by means of alamar blue assay. The compounds were tested in 
the concentration range of 100 to 0.8 µg/ml against M.tuberculosis H37Rv strain 
grown in Middlebrook 7H9 broth in 96 well titre plate. Pyrazinamide- 3.125µg/ml and 
Streptomycin- 6.25µg/ml were used as standards for comparison. A blue color in the 
well was interpreted as no bacterial growth so it is termed as sensitive, and pink color 
was scored as growth and is referred as resistant. The MIC was defined as lowest drug 
concentration which prevented the color change from blue to pink.   
Table no: 13 
Compound  Docking score MIC value 
R1 -7.62223 50 µg/ml 
R2 -8.02866 25 µg/ml 
R3 -8.52044 50 µg/ml 
 
MABA  REPORT OF THE SYNTHESISED COMPOUNDS 
                                                        Table no: 14 
S. 
No 
Sample 
100 
µg/ml 
50 
µg/ml 
25 
µg/ml 
12.5 
µg/ml 
6.25 
µg/ml 
3.12 
µg/ml 
1.6 
µg/ml 
0.8 
µg/ml 
1 R1 S S R R R R R R 
2 R2 S S S R R R R R 
3 R3 S S R R R R R R 
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Fig. Standard drug  photograph 
      
 
 
Fig. synthesized compound photograph 
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SUMMARY  
 Decaprenylphosphoryl-b-d-ribose 2’-Epimerase 1(DprE1) a enzyme of 
OxidoReductase family is a critical enzyme for the growth of Mycobacterium 
tuberculosis H37Rv.  
 From the review of literature DprE1 was chosen for our study for drug design.  
 A database of 100 molecules with high potential of inhibiting the target 
possessing PDB ID of 4FDO were carefully chosen by making changes to the 
lead molecule aryl carboxylic acid derivatives.  
 The 3D structure of the molecules were docked against the 3D structure of 
DprE1 using the docking platform argus lab.  
 Three compounds with good Docking score (lower Binding energy) were 
selected for laboratory synthesis. The reaction conditions were optimized.  
 The Compounds were labeled as R1, R2, R3 were synthesized with 
satisfactory yield  
 The purity of the synthesized compounds was ensured by repeated 
recrystallization and column chromatography.Further the compounds were 
evaluated by melting point and TLC.  
 The characterizations of the synthesized compounds were done by Infrared, 
Nuclear magnetic resonance and Mass spectroscopic methods.  
 The final pure compounds were screened for Antimycobacterial activity by in 
vitro method called Microplate Alamar Blue Assay (MABA).  
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 The synthesized compounds were active at 25mcg/ml to <100mcg/ml, which 
are compared to that of the known anti-tubercular agents at 50mcg/ml against 
the MIC of known TB drugs. The synthesized compounds were lesser active 
than that of the standard TB drugs. Pyrazinamide: 3.125mcg/ml, 
Ciprefloxacin: 3.125mcg/ml and Streptomycin 6.25mcg/ml. 
 The synthesized compounds were subjected to toxicity prediction assessments 
by OSIRS software. The results are coded as a green colour which confirms 
the drug likeness. 
CONCLUSION 
 Our work concludes that our synthesized molecules are effective in inhibiting 
Decaprenylphosphoryl-beta-D-ribose 2’-Epimerase 1(DprE1) which is 
important for the growth of Mycobacterium tuberculosis.  
 Further structural refinement in the structure of the synthesized compounds 
will give new outlook to the development of promising molecules against the 
pathogen Mycobacterium tuberculosis.  
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